Cover Image
市場調查報告書

Biotron Limited:產品平台分析

Biotron Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226204
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
Biotron Limited:產品平台分析 Biotron Limited - Product Pipeline Review - 2015
出版日期: 2015年11月25日 內容資訊: 英文 31 Pages
簡介

本報告提供Biotron Limited的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Biotron Limited的基本資料

Biotron Limited概要

  • 主要資訊
  • 企業資料

Biotron Limited:R&D概要

  • 主要的治療範圍

Biotron Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Biotron Limited:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Biotron Limited:藥物簡介

  • BIT-225
  • BIT-314
  • 登革熱用醫藥品
  • 流感用醫藥品
  • 其他標的用醫藥品

Biotron Limited:開發平台分析

Biotron Limited - 藥物各分類的開發中產品

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Biotron Limited:最近的開發平台趨勢

Biotron Limited:暫停中的計劃

Biotron Limited:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • BIT-009

Biotron Limited:企業發表

Biotron Limited:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07810CDB

Summary

Global Markets Direct's, 'Biotron Limited - Product Pipeline Review - 2015', provides an overview of the Biotron Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biotron Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biotron Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biotron Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biotron Limited's pipeline products

Reasons to buy

  • Evaluate Biotron Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biotron Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biotron Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biotron Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biotron Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biotron Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biotron Limited Snapshot
    • Biotron Limited Overview
    • Key Information
    • Key Facts
  • Biotron Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Biotron Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Biotron Limited - Pipeline Products Glance
    • Biotron Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Biotron Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Biotron Limited - Drug Profiles
    • BIT-225
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIT-314
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block M2 Proton Channel for Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit M Protein for Dengue
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biotron Limited - Pipeline Analysis
    • Biotron Limited - Pipeline Products by Target
    • Biotron Limited - Pipeline Products by Route of Administration
    • Biotron Limited - Pipeline Products by Molecule Type
    • Biotron Limited - Pipeline Products by Mechanism of Action
  • Biotron Limited - Recent Pipeline Updates
  • Biotron Limited - Dormant Projects
  • Biotron Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • BIT-009
  • Biotron Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biotron Limited, Key Information
  • Biotron Limited, Key Facts
  • Biotron Limited - Pipeline by Indication, 2015
  • Biotron Limited - Pipeline by Stage of Development, 2015
  • Biotron Limited - Monotherapy Products in Pipeline, 2015
  • Biotron Limited - Phase II, 2015
  • Biotron Limited - Preclinical, 2015
  • Biotron Limited - Discovery, 2015
  • Biotron Limited - Pipeline by Target, 2015
  • Biotron Limited - Pipeline by Route of Administration, 2015
  • Biotron Limited - Pipeline by Molecule Type, 2015
  • Biotron Limited - Pipeline Products by Mechanism of Action, 2015
  • Biotron Limited - Recent Pipeline Updates, 2015
  • Biotron Limited - Dormant Developmental Projects,2015
  • Biotron Limited - Discontinued Pipeline Products, 2015
  • Biotron Limited, Other Locations

List of Figures

  • Biotron Limited - Pipeline by Top 10 Indication, 2015
  • Biotron Limited - Pipeline by Stage of Development, 2015
  • Biotron Limited - Monotherapy Products in Pipeline, 2015
  • Biotron Limited - Pipeline by Top 10 Target, 2015
  • Biotron Limited - Pipeline by Top 10 Molecule Type, 2015
  • Biotron Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top